Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, China.
Department of Radiotherapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.
BMC Cancer. 2020 Nov 25;20(1):1146. doi: 10.1186/s12885-020-07639-x.
The value of postmastectomy radiotherapy (PMRT) for pathological node-positive triple-negative breast cancers (TNBC) remains debatable. The aim of this population-based retrospective study was to evaluate the effect of PMRT on survival outcomes in this population.
Patients diagnosed with stage T1-4N1-N3M0 TNBC between 2010 and 2014 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. We used univariate and multivariate Cox regression hazards method to determine the independent prognostic factors associated with 3-year breast cancer-specific survival (BCSS). The effect of PMRT on 3-year BCSS was analyzed after stratification by pathological staging of groups.
Of the 4398 patients included in this study, 2649 (60.2%) received PMRT. Younger age, black ethnicity, and advanced tumor (T) and nodal (N) stage were the independent predictors associated with PMRT receipt (all P < 0.05). Patients who received PMRT showed better 3-year BCSS (OR = 0.720, 95% CI = 0.642-0.808, P < 0.001) than those that did not. The effect of PMRT on 3-year BCSS was analyzed after stratification by pathological staging of groups. The results showed that PMRT was associated with better 3-year BCSS in patients with stage T3-4N1 (P = 0.042), T1-4N2 (P < 0.001), and T1-4N3 (P < 0.001), while comparable 3-year BCSS was found between the PMRT and non-PMRT cohorts with T1-2N1 disease (P = 0.191).
Radiotherapy achieved better 3-year BCSS in TNBC patients with stage T3-4N1 and T1-4N2-3 disease. However, no survival benefit was found with the addition of PMRT in patients with T1-2N1 TNBC.
对于病理淋巴结阳性三阴性乳腺癌(TNBC)患者,保乳手术后放疗(PMRT)的价值仍存在争议。本基于人群的回顾性研究旨在评估 PMRT 对该人群生存结局的影响。
从监测、流行病学和最终结果(SEER)数据库中确定 2010 年至 2014 年间诊断为 T1-4N1-N3M0 期 TNBC 的患者。我们使用单变量和多变量 Cox 回归风险方法确定与 3 年乳腺癌特异性生存(BCSS)相关的独立预后因素。通过对分组的病理分期进行分层,分析 PMRT 对 3 年 BCSS 的影响。
在纳入本研究的 4398 例患者中,2649 例(60.2%)接受了 PMRT。年龄较小、黑种人、肿瘤(T)和淋巴结(N)分期较晚是接受 PMRT 的独立预测因素(均 P<0.05)。接受 PMRT 的患者 3 年 BCSS 更好(OR=0.720,95%CI=0.642-0.808,P<0.001)。通过对分组的病理分期进行分层,分析 PMRT 对 3 年 BCSS 的影响。结果显示,在 T3-4N1(P=0.042)、T1-4N2(P<0.001)和 T1-4N3(P<0.001)患者中,PMRT 与 3 年 BCSS 相关,而在 T1-2N1 疾病患者中,PMRT 组与非 PMRT 组的 3 年 BCSS 相当(P=0.191)。
在 T3-4N1 和 T1-4N2-3 期 TNBC 患者中,放疗可获得更好的 3 年 BCSS。然而,在 T1-2N1 TNBC 患者中,添加 PMRT 并未带来生存获益。